- Home
- BLZE vs ERAS Comparison
BLZE vs ERAS Comparison
Compare BLZE & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLZE
- ERAS
- Stock Information
- Founded
- BLZE 2007
- ERAS 2018
- Country
- BLZE United States
- ERAS United States
- Employees
- BLZE N/A
- ERAS N/A
- Industry
- BLZE Computer Software: Prepackaged Software
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- BLZE Technology
- ERAS Health Care
- Exchange
- BLZE Nasdaq
- ERAS Nasdaq
- Market Cap
- BLZE 326.5M
- ERAS 348.4M
- IPO Year
- BLZE 2021
- ERAS 2021
- Fundamental
- Price
- BLZE $5.36
- ERAS $1.36
- Analyst Decision
- BLZE Strong Buy
- ERAS Strong Buy
- Analyst Count
- BLZE 7
- ERAS 6
- Target Price
- BLZE $10.29
- ERAS $4.83
- AVG Volume (30 Days)
- BLZE 386.9K
- ERAS 1.3M
- Earning Date
- BLZE 08-07-2025
- ERAS 08-11-2025
- Dividend Yield
- BLZE N/A
- ERAS N/A
- EPS Growth
- BLZE N/A
- ERAS N/A
- EPS
- BLZE N/A
- ERAS N/A
- Revenue
- BLZE $132,273,000.00
- ERAS N/A
- Revenue This Year
- BLZE $16.08
- ERAS N/A
- Revenue Next Year
- BLZE $13.97
- ERAS N/A
- P/E Ratio
- BLZE N/A
- ERAS N/A
- Revenue Growth
- BLZE 21.81
- ERAS N/A
- 52 Week Low
- BLZE $3.94
- ERAS $1.01
- 52 Week High
- BLZE $8.08
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- BLZE 49.98
- ERAS 43.53
- Support Level
- BLZE $5.29
- ERAS $1.21
- Resistance Level
- BLZE $5.60
- ERAS $1.45
- Average True Range (ATR)
- BLZE 0.22
- ERAS 0.11
- MACD
- BLZE 0.00
- ERAS -0.03
- Stochastic Oscillator
- BLZE 59.82
- ERAS 19.75
About BLZE Backblaze Inc.
Backblaze Inc provides cloud storage services. The company offers services such as Backblaze B2 Cloud Storage, which enables customers to store data, developers to build applications, and partners to expand their use cases. It is offered as a consumption-based Infrastructure-as-a-Service (IaaS) and serves use cases including backups, multi-cloud, application development, and ransomware protection and Backblaze Computer Backup automatically backs up data from laptops and desktops for businesses and individuals. Geographically, it derives a majority of revenue from the United States and the rest from the United Kingdom, Canada, and Other regions.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.